David Nierengarten is ranked #2234 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

David Nierengarten (Wedbush) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are David Nierengarten's stock ratings?

About 44% of David's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/David Nierengarten

WEDB

David Nierengarten

Wedbush

Wall Street Analyst

★★☆☆☆

#2234

on 13Foresight · ranked by our own returns

44%

Success Rate

+1.7%

Average Return

25 of 57 calls profitable · -7.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 44% of David Nierengarten's ratings turned a profit when each position was held for 1 year — averaging +1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

123 Buy 9 Hold 3 Sell

David's Stock Coverage 57 ratings · 2026-06-18

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ODTX Odyssey Therapeutics, Inc.	Jun 16, 2026	BUY	Strong Buy +52.9% avg upside 5 analysts	$30.00 62.25% Upside	·
DMRA Damora Therapeutics	Jun 16, 2026	BUY	Strong Buy +26.5% avg upside 19 analysts	$35.00 63.32% Upside	·
IRON Disc Medicine	Jun 16, 2026	BUY	Strong Buy +21.2% avg upside 21 analysts	$88.00 25.28% Upside	·
SYRE Spyre Therapeutics	Jun 16, 2026	BUY	Strong Buy -14.3% avg upside 23 analysts	$100.00 14.29% Upside	·
ARGX Argenx Se	Jun 15, 2026	BUY	Strong Buy -16.4% avg upside 46 analysts	$1000.00 12.07% Upside	+0.0%
COGT Cogent Biosciences	Jun 15, 2026	BUY	Strong Buy +9.2% avg upside 26 analysts	$55.00 63.39% Upside	+3.2%
NUVL Nuvalent	Jun 10, 2026	HOLD	Buy -0.2% avg upside 21 analysts	$124.00 0.45% Upside	+0.0%
CATX Perspective Therapeutics	Jun 04, 2026	BUY	Strong Buy +274.8% avg upside 22 analysts	$11.00 269.06% Upside	-9.8%
ABVX Abivax SA Sponsored ADR	Jun 02, 2026	HOLD	Strong Buy +20.4% avg upside 15 analysts	$90.00 10.15% Downside	+38.1%
APGE Apogee Therapeutics	May 27, 2026	BUY	Strong Buy +31.2% avg upside 19 analysts	$135.00 52.72% Upside	+13.7%
COAG Hemab Therapeutics Holdings, Inc.	May 26, 2026	BUY	Strong Buy +54.8% avg upside 5 analysts	$42.00 58.74% Upside	·
STRO Sutro Biopharma	May 18, 2026	BUY	Strong Buy +37.1% avg upside 20 analysts	$60.00 111.24% Upside	-16.5%
ORKA Oruka Therapeutics	May 14, 2026	BUY	Strong Buy +62.9% avg upside 16 analysts	$165.00 132.72% Upside	+9.4%
ZBIO Zenas BioPharma, Inc.	May 14, 2026	BUY	Strong Buy +110.8% avg upside 11 analysts	$45.00 142.22% Upside	-3.8%
BBOT BridgeBio Oncology Therapeutics	May 13, 2026	BUY	Strong Buy +227.0% avg upside 10 analysts	$25.00 225.43% Upside	-5.0%
STTK Shattuck Labs	May 08, 2026	BUY	Strong Buy +387.3% avg upside 14 analysts	$11.00 132.05% Upside	-36.8%
BEAM Beam Therapeutics	May 08, 2026	BUY	Strong Buy +57.5% avg upside 25 analysts	$65.00 100.04% Upside	-9.0%
TCRX TScan Therapeutics	May 07, 2026	BUY	Strong Buy +836.7% avg upside 12 analysts	$5.00 455.65% Upside	-25.6%
NUVB Nuvation Bio	May 05, 2026	BUY	Strong Buy +140.8% avg upside 15 analysts	$11.00 106.28% Upside	+10.3%
KNSA Kiniksa Pharmaceuticals	Apr 29, 2026	BUY	Strong Buy +1.0% avg upside 11 analysts	$59.00 8.91% Upside	-1.2%
ANAB AnaptysBio	Mar 31, 2026	BUY	Strong Buy +28.1% avg upside 26 analysts	$75.00 32.15% Upside	+55.8%
ORIC Oric Pharmaceuticals	Feb 24, 2026	BUY	Strong Buy +176.0% avg upside 19 analysts	$20.00 131.82% Upside	-38.4%
SE:HNSA Hansa Biopharma AB	Jan 07, 2026	BUY	Strong Buy +333.8% avg upside 4 analysts	$69.00 110.51% Upside	·
ARTV Artiva Biotherapeutics, Inc.	Dec 18, 2025	BUY	Strong Buy +235.3% avg upside 7 analysts	$23.00 131.42% Upside	+122.4%
RARE Ultragenyx Pharmaceutical	Oct 14, 2025	HOLD	Strong Buy +144.1% avg upside 36 analysts	$35.00 30.07% Upside	-27.1%
NVCR NovoCure	Oct 13, 2025	HOLD	Strong Buy +212.7% avg upside 11 analysts	$18.00 0.93% Upside	+32.8%
XNCR Xencor	Sep 02, 2025	BUY	Strong Buy +157.0% avg upside 27 analysts	$26.00 103.36% Upside	+31.8%
VOR Vor Biopharma	Jun 26, 2025	HOLD	Buy +190.9% avg upside 17 analysts	$8.00 46.81% Downside	-21.0%
BCAX Bicara Therapeutics Inc.	May 23, 2025	BUY	Strong Buy +35.4% avg upside 14 analysts	$30.00 30.91% Upside	+133.9%
FATE Fate Therapeutics	May 14, 2025	HOLD	Buy +512.6% avg upside 31 analysts	$5.00 155.04% Upside	+97.9%
IMNM Immunome	Mar 20, 2025	BUY	Strong Buy +85.6% avg upside 16 analysts	$33.00 78.02% Upside	+131.1%
SRRK Scholar Rock Holding	Mar 17, 2025	BUY	Strong Buy +21.1% avg upside 23 analysts	$50.00 6.49% Upside	+17.2%
IMA ImageneBio	Aug 09, 2024	HOLD	Strong Buy +195.6% avg upside 12 analysts	$2.00 64.83% Downside	-24.8%
PRME Prime Medicine, Inc.	Apr 02, 2024	BUY	Strong Buy +215.8% avg upside 16 analysts	$12.00 279.81% Upside	-71.7%
KPTI Karyopharm Therapeutics	Jul 26, 2023	HOLD	Strong Buy +139.5% avg upside 18 analysts	$4.00 57.50% Downside	-43.9%
TECX Tectonic Therapeutic	Jul 12, 2023	HOLD	Strong Buy +88.0% avg upside 24 analysts	$2.00 93.44% Downside	-1.3%
DNTH Dianthus Therapeutics	Jan 26, 2023	HOLD	Strong Buy +9.8% avg upside 29 analysts	$16.00 80.36% Downside	+154.0%
TSE:FRX Fennec Pharmaceuticals	Jan 25, 2023	BUY	Strong Buy +77.8% avg upside 9 analysts	$23.76 87.16% Upside	·
FENC Fennec Pharmaceuticals	Jan 25, 2023	BUY	Strong Buy +79.6% avg upside 9 analysts	$17.00 89.23% Upside	+4.7%
NTLA Intellia Therapeutics	Nov 03, 2022	HOLD	Buy +158.2% avg upside 37 analysts	$53.00 248.74% Upside	-44.3%
MGNX MacroGenics	Jun 16, 2021	BUY	Buy +341.3% avg upside 25 analysts	$32.00 708.08% Upside	-89.2%
GB:0QW0 arGEN X	Mar 04, 2021	BUY	Strong Buy -22.6% avg upside 24 analysts	$302.05 60.71% Downside	·
SYRS Syros Pharmaceuticals	Aug 07, 2020	HOLD	Buy +2937400.0% avg upside 9 analysts	$10.00 2499900.02% Upside	-61.6%
VYGR Voyager Therapeutics	Jun 18, 2019	BUY	Strong Buy +291.9% avg upside 23 analysts	$36.00 894.38% Upside	-53.2%
DDS Dillard's	Aug 16, 2018	BUY	Sell -44.8% avg upside 8 analysts	$95.00 83.02% Downside	-26.6%
PRTA Prothena	Apr 23, 2018	HOLD	Buy +171.8% avg upside 14 analysts	$13.00 53.10% Upside	-2.8%
KURA Kura Oncology	Dec 21, 2017	BUY	Strong Buy +170.6% avg upside 26 analysts	$19.00 98.45% Upside	-13.1%
SYBX Synlogic	Nov 28, 2017	BUY	Buy +3290.3% avg upside 11 analysts	$20.00 2716.85% Upside	-14.7%
ARDX Ardelyx	Oct 12, 2017	BUY	Strong Buy +132.3% avg upside 21 analysts	$16.00 174.07% Upside	-52.6%
NOVN Novan	Jan 30, 2017	HOLD	Buy 6 analysts	$6.00	·
IRWD Ironwood Pharma	Oct 24, 2016	HOLD	Hold +236.0% avg upside 23 analysts	$13.00 269.38% Upside	+7.6%
INFIQ Infinity Pharmaceuticals	Aug 10, 2016	HOLD	Buy +647142757.1% avg upside 8 analysts	$1.00 99999899.95% Upside	-22.5%
LITS Lite Strategy	Aug 03, 2016	HOLD	Buy +1102.6% avg upside 13 analysts	$2.00 117.53% Upside	·
CLDX Celldex	May 09, 2016	HOLD	Strong Buy +18.8% avg upside 28 analysts	$3.00 90.83% Downside	-19.4%
DARE Daré Bioscience	Nov 17, 2015	BUY	Strong Buy +541.3% avg upside 14 analysts	$9.00 332.64% Upside	-73.9%
INSM Insmed	Mar 31, 2014	SELL	Strong Buy +80.3% avg upside 36 analysts	—	-9.2%
BAX Baxter International	Mar 22, 2013	HOLD	Hold +51.7% avg upside 23 analysts	—	-1.8%

🔒 52 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

David Nierengarten — Frequently Asked Questions

How accurate are David Nierengarten's stock ratings?

Based on the calls 13Foresight could measure, about 44% of David's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, or -7.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is David ranked on 13Foresight?

David Nierengarten is currently ranked #2234 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does David cover?

David most recently has ratings on ODTX, DMRA, IRON, SYRE, ARGX, COGT, NUVL, CATX, ABVX, APGE, COAG, STRO and 45 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!